Vancomycin: Over 50 years later and still a work in progress

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1253-1255

  Rybak, Michael J ^a   Rotschafer, John C ^b   Rodvold, Keith A ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

pediatric vancomycin dosing; vancomycin consensus guidelines; Vancomycin dosing; vancomycin MAP Bayesian estimates

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

AGE; AREA UNDER THE CURVE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CONCENTRATION RESPONSE; CONSENSUS DEVELOPMENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; DRUG RESEARCH; EDITORIAL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; STAPHYLOCOCCUS INFECTION; STEADY STATE; ADULT; CHILD; DOSE RESPONSE; METHODOLOGY; PEDIATRIC VANCOMYCIN DOSING; PRACTICE GUIDELINE; VANCOMYCIN CONSENSUS GUIDELINES; VANCOMYCIN DOSING; VANCOMYCIN MAP BAYESIAN ESTIMATES;

PEDIATRIC VANCOMYCIN DOSING; VANCOMYCIN CONSENSUS GUIDELINES; VANCOMYCIN DOSING; VANCOMYCIN MAP BAYESIAN ESTIMATES;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; PRACTICE GUIDELINES AS TOPIC; VANCOMYCIN;

EID: 84900849375     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1382     Document Type: Editorial

References (7)

1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 1: 82-98.
2. Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ,. Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S hospitals. Pharmacotherapy 2013; 33: 1256-1263.
3. Yang Y, McBride MV, Rodvold KA, et al. Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010; 12: 1017-24.
4. Madigan T, Sieve RM, Graner KK, Banerjee R,. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy 2013; 33: 1264-1272.
5. Heble DE Jr, McPherson C, Nelson MP, Hunstad DA,. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy 2013; 33: 1273-1277.
6. Camaione L, Elliott K, Mitchell-Van Steele A, Lomaestro B, Pai MP,. Vancomycin dosing in children and young adults: back to the drawing board. Pharmacotherapy 2013; 33: 1278-1287.
7. Stockmann C, Sherwin CM, Zobell JT, et al. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy 2013; 33: 1288-1296.